Brenton Flynn, Motley Fool health care bureau chief, discusses AbbVie. Like other pharmaceutical companies, this company serves a non-cyclical market of consumers that aren't very price-conscious. He then addresses specific advantages that AbbVie enjoys, naming three reasons to buy the stock:
- Humira's pipeline -- AbbVie has a tremendous opportunity to serve hepatitis C patients, of whom there are 170 million worldwide.
- Concerns about Humira are overdone. Humira is a biologic, which is more difficult to copy than other small molecule drugs.
- AbbVie has one of the top dividends among big pharma, sporting a 4% yield.
Follow along in the video below to learn more about each of these reasons you might consider buying AbbVie for your portfolio.